Cargando…
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy
BACKGROUND: Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation of the kinetic mou...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494095/ https://www.ncbi.nlm.nih.gov/pubmed/32936818 http://dx.doi.org/10.1371/journal.pntd.0008583 |
_version_ | 1783582683098513408 |
---|---|
author | Lenz, Shannon M. Collins, Jaymes H. Ray, Nashone A. Hagge, Deanna A. Lahiri, Ramanuj Adams, Linda B. |
author_facet | Lenz, Shannon M. Collins, Jaymes H. Ray, Nashone A. Hagge, Deanna A. Lahiri, Ramanuj Adams, Linda B. |
author_sort | Lenz, Shannon M. |
collection | PubMed |
description | BACKGROUND: Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation of the kinetic mouse footpad (MFP) screening assay to aid in the choice of drugs and regimens for clinical trials. METHODOLOGY/PRINCIPAL FINDINGS: Athymic nude mice were inoculated in the footpad (FP) with 6 x 10(3) viable M. leprae and treated by gastric gavage with a single dose of Rifampin (SDR), Rifampin + Ofloxacin + Minocycline (SD-ROM), or Rifapentine + Minocycline + Moxifloxacin (SD-PMM) or with the proposed PEP++ regimen of three once-monthly doses of Rifampin + Moxifloxacin (RM), Rifampin + Clarithromycin (RC), Rifapentine + Moxifloxacin (PM), or Rifapentine + Clarithromycin (PC). At various times post-treatment, DNA was purified from the FP, and M. leprae were enumerated by RLEP quantitative PCR. A regression analysis was calculated to determine the expected RLEP value if 99.9% of the bacilli were killed after the administration of each regimen. SDR and SD-ROM induced little growth delay in this highly susceptible murine model of subclinical infection. In contrast, SD-PMM delayed measurable M. leprae growth above the inoculum by 8 months. The four multi-dose regimens delayed bacterial growth for >9months post-treatment cessation. CONCLUSIONS/SIGNIFICANCE: The delay in discernable M. leprae growth post-treatment was an excellent indicator of drug efficacy for both early (3–4 months) and late (8–9 months) drug efficacy. Our data indicates that multi-dose PEP may be required to control infection in highly susceptible individuals with subclinical leprosy to prevent disease and decrease transmission. |
format | Online Article Text |
id | pubmed-7494095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-74940952020-09-24 Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy Lenz, Shannon M. Collins, Jaymes H. Ray, Nashone A. Hagge, Deanna A. Lahiri, Ramanuj Adams, Linda B. PLoS Negl Trop Dis Research Article BACKGROUND: Subclinical infection with Mycobacterium leprae is one potential source of leprosy transmission, and post-exposure prophylaxis (PEP) regimens have been proposed to control this source. Because PEP trials require considerable investment, we applied a sensitive variation of the kinetic mouse footpad (MFP) screening assay to aid in the choice of drugs and regimens for clinical trials. METHODOLOGY/PRINCIPAL FINDINGS: Athymic nude mice were inoculated in the footpad (FP) with 6 x 10(3) viable M. leprae and treated by gastric gavage with a single dose of Rifampin (SDR), Rifampin + Ofloxacin + Minocycline (SD-ROM), or Rifapentine + Minocycline + Moxifloxacin (SD-PMM) or with the proposed PEP++ regimen of three once-monthly doses of Rifampin + Moxifloxacin (RM), Rifampin + Clarithromycin (RC), Rifapentine + Moxifloxacin (PM), or Rifapentine + Clarithromycin (PC). At various times post-treatment, DNA was purified from the FP, and M. leprae were enumerated by RLEP quantitative PCR. A regression analysis was calculated to determine the expected RLEP value if 99.9% of the bacilli were killed after the administration of each regimen. SDR and SD-ROM induced little growth delay in this highly susceptible murine model of subclinical infection. In contrast, SD-PMM delayed measurable M. leprae growth above the inoculum by 8 months. The four multi-dose regimens delayed bacterial growth for >9months post-treatment cessation. CONCLUSIONS/SIGNIFICANCE: The delay in discernable M. leprae growth post-treatment was an excellent indicator of drug efficacy for both early (3–4 months) and late (8–9 months) drug efficacy. Our data indicates that multi-dose PEP may be required to control infection in highly susceptible individuals with subclinical leprosy to prevent disease and decrease transmission. Public Library of Science 2020-09-16 /pmc/articles/PMC7494095/ /pubmed/32936818 http://dx.doi.org/10.1371/journal.pntd.0008583 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Lenz, Shannon M. Collins, Jaymes H. Ray, Nashone A. Hagge, Deanna A. Lahiri, Ramanuj Adams, Linda B. Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
title | Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
title_full | Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
title_fullStr | Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
title_full_unstemmed | Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
title_short | Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
title_sort | post-exposure prophylaxis (pep) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494095/ https://www.ncbi.nlm.nih.gov/pubmed/32936818 http://dx.doi.org/10.1371/journal.pntd.0008583 |
work_keys_str_mv | AT lenzshannonm postexposureprophylaxispepefficacyofrifampinrifapentinemoxifloxacinminocyclineandclarithromycininasusceptiblesubclinicalmodelofleprosy AT collinsjaymesh postexposureprophylaxispepefficacyofrifampinrifapentinemoxifloxacinminocyclineandclarithromycininasusceptiblesubclinicalmodelofleprosy AT raynashonea postexposureprophylaxispepefficacyofrifampinrifapentinemoxifloxacinminocyclineandclarithromycininasusceptiblesubclinicalmodelofleprosy AT haggedeannaa postexposureprophylaxispepefficacyofrifampinrifapentinemoxifloxacinminocyclineandclarithromycininasusceptiblesubclinicalmodelofleprosy AT lahiriramanuj postexposureprophylaxispepefficacyofrifampinrifapentinemoxifloxacinminocyclineandclarithromycininasusceptiblesubclinicalmodelofleprosy AT adamslindab postexposureprophylaxispepefficacyofrifampinrifapentinemoxifloxacinminocyclineandclarithromycininasusceptiblesubclinicalmodelofleprosy |